Journal
CURRENT ONCOLOGY REPORTS
Volume 13, Issue 1, Pages 42-49Publisher
SPRINGER
DOI: 10.1007/s11912-010-0144-x
Keywords
Biomarkers; Glioma; Neurooncology trials; Biomarker enrichment design; Marker by treatment interaction design; Adaptive design
Categories
Funding
- Merck
- Millenium
- Basilea
- Bristol-Meyers Squibb
- Array Biopharma
- Lilly
- Novartis
- Schering
- Merck KGaA
- [CA-108961]
Ask authors/readers for more resources
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available